New antibody drug shows promise for Tough-to-Treat myeloma
NCT ID NCT03933735
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study tests a new drug called TNB-383B in people with multiple myeloma that has come back or not responded to at least three prior treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find the safest dose and see how well it controls the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Levine Cancer Institute /ID# 238786
Charlotte, North Carolina, 28204, United States
-
Atrium Health Wake Forest Baptist Medical Center /ID# 238787
Winston-Salem, North Carolina, 27157, United States
-
Duplicate_Universitaetsklinikum Muenster /ID# 239637
Münster, North Rhine-Westphalia, 48149, Germany
-
Mayo Clinic - Rochester /ID# 238683
Rochester, Minnesota, 55905-0001, United States
-
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 244831
New York, New York, 10065-6007, United States
-
Mt Sinai /ID# 242317
New York, New York, 10029-6542, United States
-
Tulane University School of Medicine /ID# 242322
New Orleans, Louisiana, 70112, United States
-
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 239638
Dresden, Saxony, 01307, Germany
-
Universitaetsklinikum Hamburg-Eppendorf /ID# 239636
Hamburg, 20246, Germany
-
Universitaetsklinikum Koeln /ID# 239676
Cologne, North Rhine-Westphalia, 50937, Germany
-
University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680
San Francisco, California, 94143, United States
-
University of North Carolina /ID# 238685
Chapel Hill, North Carolina, 27514, United States
-
Washington University-School of Medicine /ID# 238681
St Louis, Missouri, 63110, United States
-
Wisconsin Medical Center /ID# 238684
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.